2259. Reversal of antimicrobial consumption: long-term impact of COVID-19 pandemic

BACKGROUND: The global decrease in antimicrobial consumption (AMC) in 2020 has been associated with the COVID-19 pandemic. However, it is not clear whether this downward trend will continue. Several reports, including ESAC-Net, have documented an increase in antimicrobial use after a decrease in antimicrobial consumption following the COVID-19 pandemic in some countries. The aim of this study is to examine the global trend in AMC following the emergence of COVID-19 in the long term. METHODS: After comparing the change rate of AMC in 67 countries’ using IQVIA MIDAS(®) monthly sales data of antimicrobials between 2019 and 2020 and between 2021 and 2022, changepoint detection was conducted in time-series data from November 2016 to October 2022. Additionally, we examined the impact of implementation and lifting of movement restriction in G7 countries by interrupted time-series analysis (ITSA). RESULTS: In the IQVIA MIDAS sales data, 65 among 67 countries have one or two changepoints (Table1). 59 among 65 countries experienced a decrease in AMC after the beginning of COVID-19 pandemic. However, 50 among 59 countries showed reversal increase trend of AMC in 2022 (Figure1). ITSA showed that implementation of movement restriction had negative impact on AMC in all G7 countries (Figure2). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: The global decrease in AMC in 2020 may not be due to COVID-19 itself, but to non-pharmaceutical interventions such as movement restrictions. Human mobility may be one of the key determinants of antimicrobial use at the population level. DISCLOSURES: All Authors: No reported disclosures